929713-54-2Relevant articles and documents
Optimization of GPR40 agonists for type 2 diabetes
Liu, Jiwen,Wang, Yingcai,Ma, Zhihua,Schmitt, Mike,Zhu, Liusheng,Brown, Sean P.,Dransfield, Paul J.,Sun, Ying,Sharma, Rajiv,Guo, Qi,Zhuang, Run,Zhang, Jane,Luo, Jian,Tonn, George R.,Wong, Simon,Swaminath, Gayathri,Medina, Julio C.,Lin, Daniel C.-H.,Houze, Jonathan B.
supporting information, p. 517 - 521 (2014/06/09)
GPR40 (FFA1 and FFAR1) has gained significant interest as a target for the treatment of type 2 diabetes. TAK-875 (1), a GPR40 agonist, lowered hemoglobin A1c (HbA1c) and lowered both postprandial and fasting blood glucose levels in type 2 diabetic patient